Provided by Tiger Trade Technology Pte. Ltd.

Beam Therapeutics, Inc.

25.60
-1.1600-4.33%
Post-market: 25.630.0300+0.12%17:35 EST
Volume:1.46M
Turnover:38.33M
Market Cap:2.60B
PE:-5.79
High:27.87
Open:26.80
Low:25.53
Close:26.76
52wk High:35.25
52wk Low:13.53
Shares:101.47M
Float Shares:89.94M
Volume Ratio:0.93
T/O Rate:1.62%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.4193
EPS(LYR):-4.5769
ROE:-47.19%
ROA:-23.48%
PB:2.69
PE(LYR):-5.59

Loading ...

Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM) and Disc Medicine (IRON)

TIPRANKS
·
Oct 17

U.S. RESEARCH ROUNDUP-Beacon Financial, Comerica, Doximity

Reuters
·
Oct 10

Beam Therapeutics Inc : Jefferies Initiates Coverage With Buy Rating: Target Price $41

THOMSON REUTERS
·
Oct 10

Beam Therapeutics initiated with a Buy at Jefferies

TIPRANKS
·
Oct 09

Can Analyst Optimism Around BEAM's Base Editing Progress Reveal Its Edge in Genetic Disease Treatment?

Simply Wall St.
·
Oct 09

Beam Therapeutics Inc : JP Morgan Cuts Target Price to $46 From $48

THOMSON REUTERS
·
Oct 09

AI Biotech Stocks Shined. Ginkgo Up 12%; Recursion And Crispr Up 8%; Tempus And Hims & Hers Up 3%

Tiger Newspress
·
Oct 08

Beam Therapeutics CEO John M. Evans Reports Disposal of Common Shares

Reuters
·
Oct 04

Cathie Wood’s ARK Investment buys 491K shares of Beam Therapeutics today

TIPRANKS
·
Sep 18

Beam Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 15

Beam Therapeutics Inc. to Participate in Citi's Biopharma Back to School Conference

Reuters
·
Aug 25

BUZZ-U.S. STOCKS ON THE MOVE-Oracle, Kratos, Masimo

Reuters
·
Aug 14

Beam Therapeutics Shares up 1.5% Premarket After U.S. FDA's Tag for Sickle Cell Disease Therapy

THOMSON REUTERS
·
Aug 14

Beam Therapeutics Secures FDA Regenerative Medicine Advanced Therapy Designation for BEAM-101 in Sickle Cell Disease Treatment

Reuters
·
Aug 14

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (Rmat) Designation Granted to Beam-101 for the Treatment of Sickle Cell Disease

THOMSON REUTERS
·
Aug 14

Beam Therapeutics Is Maintained at Equal-Weight by Barclays

Dow Jones
·
Aug 06

Stock Track | Beam Therapeutics Plummets 5% as Barclays Slashes Price Target

Stock Track
·
Aug 06

Stock Track | Beam Therapeutics Plummets 5% as Barclays Slashes Price Target

Stock Track
·
Aug 06

Beam Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 05

Beam Therapeutics Q2 EPS $(1.00) Beats $(1.12) Estimate, Sales $8.47M Miss $13.56M Estimate

Benzinga
·
Aug 05